The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics

Laura C Coates; William Tillett; David Chandler; Philip S Helliwell; Eleanor Korendowych; Stuart Kyle; Iain B McInnes; Susan Oliver; Anthony Ormerod; Catherine Smith; Deborah Symmons; Nicola Waldron; Neil J McHugh; BSR Clinical Affairs Committee & Standards, Audit and Guidelines Working Group and the BHPR

doi:10.1093/rheumatology/ket187

The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics

Rheumatology (Oxford). 2013 Oct;52(10):1754-7. doi: 10.1093/rheumatology/ket187. Epub 2013 Jul 25.

Authors

Laura C Coates¹, William Tillett, David Chandler, Philip S Helliwell, Eleanor Korendowych, Stuart Kyle, Iain B McInnes, Susan Oliver, Anthony Ormerod, Catherine Smith, Deborah Symmons, Nicola Waldron, Neil J McHugh; BSR Clinical Affairs Committee & Standards, Audit and Guidelines Working Group and the BHPR

Affiliation

¹ Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath BA1 1RL, UK. neil.mchugh@rnhrd.nhs.uk.

PMID: 23887065
DOI: 10.1093/rheumatology/ket187

No abstract available

Keywords: anti-TNF therapies; biologics; dactylitis; enthesitis; guidelines; management; psoriasis; psoriatic arthritis; recommendations; treatment.

Publication types

Practice Guideline

MeSH terms

Algorithms
Antirheumatic Agents / adverse effects
Antirheumatic Agents / therapeutic use*
Arthritis, Psoriatic / drug therapy*
Biological Products / adverse effects
Biological Products / therapeutic use*
Humans
Treatment Failure
Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

Antirheumatic Agents
Biological Products
Tumor Necrosis Factor-alpha